Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [41] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [42] Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions
    Stephanie PL Saw
    Mei-Kim Ang
    Daniel SW Tan
    Current Treatment Options in Oncology, 2022, 23 : 1721 - 1731
  • [43] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    Oncology and Therapy, 2022, 10 : 13 - 22
  • [44] Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
    Xiao-Ming Jiang
    Yu-Lian Xu
    Mu-Yang Huang
    Le-Le Zhang
    Min-Xia Su
    Xiuping Chen
    Jin-Jian Lu
    Acta Pharmacologica Sinica, 2017, 38 : 1512 - 1520
  • [45] Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Wakelee, Heather A.
    Hui, Angela Bik-Yu
    Padda, Sukhmani K.
    Joshi, Nitin D.
    Guo, H. Henry
    Chaudhuri, Aadel
    Diehn, Maximilian
    Loo, Billy W.
    Neal, Joel W.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
  • [46] Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
    Jiang, Xiao-Ming
    Xu, Yu-Lian
    Huang, Mu-Yang
    Zhang, Le-Le
    Su, Min-Xia
    Chen, Xiuping
    Lu, Jin-Jian
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (11) : 1512 - 1520
  • [47] Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China
    Mu, Lifeng
    Liu, Fulin
    Fang, Yulan
    He, Mei
    Yang, Ming
    BMJ OPEN, 2024, 14 (08):
  • [48] Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer
    Facchinetti, Francesco
    Bozzetti, Francesca
    Minari, Roberta
    Ceccon, Giovanni
    Zielli, Teresa
    Florindo, Irene
    Crisi, Girolamo
    Tiseo, Marcello
    TUMORI JOURNAL, 2018, 104 (06): : NP29 - NP33
  • [49] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
    Arulananda, Surein
    Do, Hongdo
    Musafer, Ashan
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1728 - 1732
  • [50] Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Liu, Gordon
    Xie, Feng
    Sheng, Yanan
    Shi, Luwen
    CLINICAL THERAPEUTICS, 2019, 41 (11) : 2308 - 2320
12345